BSX Stock Price Today (April 2026) — Boston Scientific Corporation Analysis & Key Metrics 2026-04-02
Boston Scientific Corporation (BSX) is trading at $60.83, down 1.89% today (as of April 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $101.25 (66.4% upside).
- Volatility remains elevated (38.06% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (15.90% YoY) alongside significant competitive pressures.
BSX Stock Analysis: Key Metrics & Valuation (April 2026)
Concise, actionable data for investors
Boston Scientific Corporation - Historical Price & Volume
Market Cap
Enterprise Value: $103.46B
P/E Ratio
Forward P/E: 16.07
Revenue Growth
Year over Year
Analyst Target
+66.4% upside potential
Key Investor Questions About BSX
What investors need to know before buying
Based on current market data, BSX presents a oversold technical setup with caution warranted fundamentals.
- Technicals say: Oversold (RSI 25.93)
- Fundamentals say: Caution warranted (high leverage concerns)
BSX's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BSX investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $11.97B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, BSX stock traded between $61.25 and $109.50—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 38.06% annualized volatility and β=0.70, the stock exhibits low sensitivity to market moves—making BSX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Tired of AI and Oil? Buy the Robot.
Intuitive Surgical (ISRG) is currently hovering around the $450 mark, a level that has historically acted as a psychological and technical floor. For an investor, the question isn't just "is it cheap?" (it almost never is), but "is the premium still justified?”.
Is It Time To Revisit Boston Scientific (BSX) After This Year’s Sharp Share Price Pullback
Investors may be wondering if Boston Scientific at around US$61.86 is starting to look attractive, or if the recent pullback is hinting at deeper valuation questions. The stock is down about 1.4% over the last week, 13.3% over the last month, and 34.7% year to date, with a 31.8% decline over 1 year, while the 3 and 5 year returns sit at 21.9% and 57.0% respectively. These moves are set against a backdrop of ongoing attention on Boston Scientific's role in the medical device space and how...
Boston Scientific (BSX) Stock Sinks As Market Gains: Here's Why
In the most recent trading session, Boston Scientific (BSX) closed at $61.86, indicating a -1.17% shift from the previous trading day.
Leerink Reiterates Outperform on Boston Scientific (BSX) After CHAMPION-AF Readout
Boston Scientific Corporation (NYSE:BSX) is one of the 8 Most Oversold Strong Buy-Rated Stocks to Invest In. On March 30, 2026, Leerink analyst Mike Kratky said Boston Scientific Corporation (NYSE:BSX) CHAMPION-AF readout met both primary safety and efficacy endpoints, as expected, with results presented at ACC. Mike Kratky noted some nuances in the data that […]
J&J launches enhanced PFA device in Europe
The Varipulse Pro pulsed field ablation platform, which has received a CE mark, will be a focus at the upcoming European Heart Rhythm Association annual meeting in Paris.
3 of Wall Street’s Favorite Stocks for Long-Term Investors
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Boston Scientific closes buyout of Valencia Technologies
The deal positions Boston Scientific to compete with Medtronic for a market that analysts believe is highly under-penetrated.
We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Boston Scientific's 2026 Guidance 'Reasonable', RBC Says
Boston Scientific's (BSX) 2026 guidance is "reasonable", but stock sentiment is being driven by the
JNJ Q1 MedTech Preview: Key Drivers and China Headwinds to Watch
JNJ's MedTech unit rides cardiovascular strength and new product adoption, but China headwinds loom ahead of its Q1 earnings release.
Frequently Asked Questions
Common investor questions about Boston Scientific Corporation
Boston Scientific Corporation (BSX) is currently trading at $60.83. The RSI (14-day) is at 25.9, indicating oversold territory (potentially undervalued). Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $101.25 implies 66.4% upside from current levels. Volatility is moderate at 38.1% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Boston Scientific Corporation (BSX): The trailing P/E ratio is 32.38, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 16.07, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.68, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 3.84. Price-to-Sales is 4.65. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 32 analysts covering BSX, the consensus price target is $101.25. This represents a 66.4% upside from the current price of $60.83. The range spans from a low target of $83.00 to a high target of $124.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Boston Scientific Corporation (BSX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Boston Scientific Corporation (BSX) investors include: 1. Moderate volatility (38.1% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Boston Scientific Corporation's (BSX) current debt and financial health profile: Total debt stands at $11.97B. The debt-to-equity ratio is 48.92, which is moderate and generally manageable for most companies. The current ratio is 1.62, indicating strong short-term liquidity. The quick ratio is 0.90. The company holds $1.96B in cash and equivalents. Free cash flow is positive at $3.24B, providing a cushion for debt servicing and shareholder returns.